AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10657761
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (CAP)
Trial: 31032742
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment (MicroLaserPeel™ and ProFractional™)
Trial: 22426952
Drug: Morning teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Morning teriparatide (20 μg daily)
Trial: 22426952
Drug: Evening teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evening teriparatide (20 μg daily)
Trial: 20722561
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg/day) for 3 months
Trial: 20722561
Drug: Stable dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable dose of ACEIs and/or ARBs
Trial: 1333741
Drug: Lysine-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine-aspirin
Trial: 30573499
Drug: Topical brimonidine
RxNorm normalized name: brimonidine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical brimonidine tartrate 0.15% administered 20 min prior to injection
Trial: 29136445
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg peanut patch
Trial: 29136445
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg peanut patch
Trial: 29136445
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg peanut patch
Trial: 29136445
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg peanut patch (6-11 years)
Trial: 29136445
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg peanut patch (adolescents/adults)
Trial: 15027519
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid 12% and pramoxine hydrochloride 1% cream applied twice daily for 7 days
Trial: 11309549
Drug: Lotrafiban (5-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban (5-100 mg, twice daily for 12 weeks)
Trial: 11309549
Drug: Lotrafiban (exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban (exposure > 835 ng.h/mL)
Trial: 11309549
Drug: Lotrafiban (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban (lower dose recommendation)
Trial: 9203727
Drug: Monoclonal antibody-based
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody-based IgM capture ELISA
Trial: 3320366
Drug: Flupenthixol 0.5
RxNorm normalized name: flupenthixol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol 0.5 mg twice daily
Trial: 18854910
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) after mitoxantrone induction (20 mg/d SC)
Trial: 18854910
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) alone (20 mg/d SC)
Trial: 12922120
Drug: Diphtheria-tetanus toxoid-acellular
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus toxoid-acellular pertussis vaccine
Trial: 10342425
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose topical capsaicin (1%)
Trial: 8641230
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at a target dosage of 800 mg/day (400 mg twice daily)
Trial: 1523351
Drug: 7 +
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 + 3 chemotherapy protocol
Trial: 1523351
Drug: TADOP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TADOP chemotherapy protocol
Trial: 7100823
Drug: Amoxycillin, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin, 50 mg/kg twice daily
Trial: 7100823
Drug: Pivampicillin, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin, 50 mg/kg twice daily
Trial: 7100823
Drug: Intramuscular ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ampicillin
Trial: 31070690
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus HAIC (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2400 mg/m2 for 46 hours, every 3 weeks)
Trial: 28270335
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care treatment as usual (TAU)
Trial: 24219891
Drug: High-fructose diet
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose diet (150 g per day for 4 weeks)
Trial: 24219891
Drug: High-glucose diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose diet (150 g per day for 4 weeks)
Trial: 9399010
Drug: Lanepitant 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanepitant 30 mg
Trial: 9399010
Drug: Lanepitant 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanepitant 80 mg
Trial: 9399010
Drug: Lanepitant 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanepitant 240 mg
Trial: 3300274
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (200 mg tid)
Trial: 30628519
Drug: sequential naïve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential naïve pinhole bone scan (nPBS)
Trial: 30628519
Drug: sequential gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential gamma correction pinhole bone scan (GCPBS)
Trial: 29543506
Drug: Lidcombe Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidcombe Program treatment
Trial: 17683491
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate 10 mg 1 hour before CE examination
Trial: 16143696
Drug: Bisoprolol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (target dose 10 mg QD)
Trial: 16143696
Drug: Enalapril (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (target dose 10 mg BID)
Trial: 2208231
Drug: Nifedipine, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 60 mg per day
Trial: 2208231
Drug: Diltiazem, 270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 270 mg per day
Trial: 2208231
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 30 mg nifedipine per day with 180 mg diltiazem per day
Trial: 2208231
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 60 mg nifedipine per day with 270 mg diltiazem per day
Trial: 7191306
Drug: Indometacin (equimolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (equimolar doses, t.i.d. for 10 days)
Trial: 7191306
Drug: Acemetacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (single dose)
Trial: 7191306
Drug: Indometacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (single dose)
Trial: 23796764
Drug: Ahmed implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed implant
Trial: 22843282
Drug: Tafamidis 20
RxNorm normalized name: TAFAMIDIS 20MG TAB UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 20 mg QD
Trial: 19423108
Drug: Pravastatin (10-20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10-20mg daily)
Trial: 9700992
Drug: Aspirin 990
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 990 mg/day plus dipyridamole 225 mg/day
Trial: 18426639
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid weekly
Trial: 7978695
Drug: 27.5 mg
RxNorm normalized name: lipase 27.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27.5 mg folic acid weekly
Trial: 7978695
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (both doses)
Trial: 2691812
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil and exercise (FE), N = 7, 50 ml of oil daily and 3 d.wk‐1 of aerobic exercise
Trial: 2691812
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (F), N = 7, 50 ml of oil daily
Trial: 2691812
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (CN), N = 10, 50 ml of oil daily
Trial: 29948869
Drug: Acetaminophen iv
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen iv (n = 63)
Trial: 21676083
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol tablets (25 µg, 4-hourly, max 5 doses)
Trial: 21676083
Drug: Vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dinoprostone (PGE2) gel (0.5 mg, 6-hourly, max 2 doses)
Trial: 18458358
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) loading (5 g dicreatine citrate plus 10 g of flavored fructose powder per packet, 20 g/d for 5 days)
Trial: 18458358
Drug: Placebo (Pl;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Pl; 10 g of flavored fructose powder per packet)
Trial: 3512226
Drug: Nonretard isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonretard isosorbide dinitrate, 20 and 40 mg six times daily
Trial: 31746542
Drug: 1% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% tetracaine hydrochloride injection pure solution aerosol inhalation combined with oral 5 mL of dyclonine hydrochloride mucilage
Trial: 31746542
Drug: Diluted tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted tetracaine hydrochloride injection (3 mL of 1% tetracaine hydrochloride injection + 3 mL of sterile water for injection) aerosol inhalation combined with oral 5 mL of dyclonine hydrochloride mucilage
Trial: 19726771
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum (0.58 mg per injection)
Trial: 18162014
Drug: Divalproex monotherapy
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex monotherapy (target dose level, 70‐90 ng/dL)
Trial: 14609035
Drug: Zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 20 mg bid for 4 weeks
Trial: 8851312
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol hydrobromide (600 micrograms) during 3-minute UNDW inhalation
Trial: 8851312
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol hydrobromide (400 micrograms) during 1-minute UNDW inhalation
Trial: 8851312
Drug: Inhaled oxitropium
RxNorm normalized name: oxitropium
DrugBank: Oxitropium (DB12086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled oxitropium bromide (300 micrograms) during 3-minute UNDW inhalation
Trial: 6418654
Drug: Balanced AA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced AA solution with 10% branched chain amino acids (BCAA)
Trial: 6418654
Drug: AA solution
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA solution with 60% BCAA
Trial: 6418654
Drug: AA solution
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA solution with 67% alanine
Trial: 2412070
Drug: Ketanserin (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (selective S2-serotonergic receptor antagonist)
Trial: 2412070
Drug: Antiplatelet therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapies
Trial: 24527467
Drug: 2 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 µg dexmedetomidine added to 3 mL (15 mg) hyperbaric bupivacaine
Trial: 24527467
Drug: 4 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 µg dexmedetomidine added to 3 mL (15 mg) hyperbaric bupivacaine
Trial: 24527467
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL saline added to 3 mL (15 mg) hyperbaric bupivacaine
Trial: 21937481
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (LAmB) plus deferasirox (20 mg/kg/day for 14 days)
Trial: 20826626
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg dihydrocapsiate/d
Trial: 20826626
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg dihydrocapsiate/d
Trial: 20826626
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg dihydrocapsiate/d)
Trial: 18379965
Drug: Multimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality therapy (including TUR, radiation, and chemotherapy)
Trial: 18379965
Drug: Organ-preserving approach
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organ-preserving approach (including TUR and intravesical therapy)
Trial: 10947687
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection peribulbar block
Trial: 1428467
Drug: Active agents
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active agents
Trial: 6230034
Drug: Ipratropium (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg)
Trial: 31205487
Drug: SPMC oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPMC oral solution
Trial: 25178112
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled fluticasone propionate (FP)
Trial: 25178112
Drug: Standard-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose inhaled fluticasone propionate (FP)
Trial: 22491567
Drug: Chlorhexidine‐gluconate (CHG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine‐gluconate (CHG) (4%) spray
Trial: 22491567
Drug: Povidone‐iodine (PI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone‐iodine (PI) (10%) spray
Trial: 16326674
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% plus lornoxicam 8 mg (Group RL)
Trial: 1806490
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone (hGH) 0.03 mg/kg subcutaneously 3 times a week for 12 months (6-18 months experimental period)
Trial: 1806490
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone (hGH)
Trial: 6613689
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ascorbic acid daily for two weeks
Trial: 6613689
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ascorbic acid daily
Trial: 31805862
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Rifampicin (SDR) at double the regular dose (20 mg/kg) provided to eligible contacts aged two years and above in arms 2, 3, and 4.
Trial: 28592299
Drug: Real biofield
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real biofield therapy
Trial: 26466314
Drug: Dietary n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary n-3 polyunsaturated fatty acids (PUFAs) intake, mean intake 2.0 ± 1.3 g/day
Trial: 26466314
Drug: Dietary alpha-linolenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary alpha-linolenic acid (ALA) intake, mean intake 1.5 ± 1.0 g/day
Trial: 26466314
Drug: Ratio of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratio of n-6/n-3 PUFAs, mean ratio 9.5 ± 6.7 g/day
Trial: 23549520
Drug: Prednisone and
RxNorm normalized name: chloroprednisone and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone and valacyclovir plus physical therapy (n = 39)
Trial: 23549520
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy only (n = 48)
Trial: 21165628
Drug: L-arabinose (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arabinose (2 g) with sucrose (40 g)
Trial: 21165628
Drug: Sucrose (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (40 g) without L-arabinose
Trial: 9413958
Drug: Oral 13-cis-retinoic
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 13-cis-retinoic acid at 20 mg/day
Trial: 9413958
Drug: Oral 13-cis-retinoic
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 13-cis-retinoic acid at 40 mg every other day
Trial: 8386921
Drug: Diltiazem (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (calcium antagonist)
Trial: 8386921
Drug: Furosemide and
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide and Atenolol (loop diuretic and beta-blocker)
Trial: 8386921
Drug: Lisinopril and
RxNorm normalized name: lisinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril and Diltiazem
Trial: 3318429
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg nabumetone once daily
Trial: 2429335
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg naproxen twice daily
Trial: 3318429
Drug: Nabumetone (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (open-label treatment)
Trial: 28426624
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg daily for 1 week, then up to 50 mg daily for 8 weeks)
Trial: 23524365
Drug: Passive control
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive control (contralateral shoulder without treatment)
Trial: 21383004
Drug: Night-time ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time ingestion of antihypertensives
Trial: 21383004
Drug: Morning ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning ingestion of antihypertensives
Trial: 19109560
Drug: Low-dose platelet
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose platelet transfusions (150-<300 x 10(9) platelets/product)
Trial: 19109560
Drug: Standard-dose platelet
RxNorm normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose platelet transfusions (300-600 x 10(9) platelets/product)
Trial: 19109560
Drug: Low-dose platelet
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose platelet transfusions
Trial: 19109560
Drug: Standard-dose platelet
RxNorm normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose platelet transfusions
Trial: 15187171
Drug: Bayley Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayley Infant Neurodevelopmental Screener (BINS) administered at 6 and 13 months
Trial: 15187171
Drug: Bayley Scales
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayley Scales of Infant Development, second edition (BSID‐II) administered at 24 months
Trial: 10211048
Drug: HF and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF and red-pepper (10 g) meal
Trial: 28390503
Drug: Interactive media‐based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive media‐based, computer‐delivered depression treatment program (imbPST)